NCT00649064View on ClinicalTrials.gov

A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

September 30, 2004

Conditions
Schizoaffective DisorderSchizophrenia
Interventions
DRUG

Ziprasidone

Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.

Trial Locations (3)

Unknown

Pfizer Investigational Site, Changhua

Pfizer Investigational Site, Tainan City

Pfizer Investigational Site, Taipei

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00649064 - A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs | Biotech Hunter | Biotech Hunter